A Case of Alpers–Huttenlocher Syndrome Due to a New POLG1 Mutation with Rapid Onset of Partial Status Epilepticus: Serial Neuroradiological and Neurophysiological Evaluation

Abstract

Alpers–Huttenlocher syndrome (AHS) is a severe and progressive neurodegenerative disease caused by mutations in the gene encoding the catalytic subunit of the mitochondrial-DNA-specific polymerase-γ (POLG1) gene. The primary features of AHS include refractory seizures, developmental regression, and hepatopathy, but these features may have varying degrees of severity and time of onset. Electroencephalogram (EEG) typically shows occipital lobe predilection, and progressive cortical atrophy with signal abnormalities and diffusion-weighted imaging (DWI) cortical-restricted diffusion are reported on brain magnetic resonance imaging (MRI). These findings may not occur or may arise later in the course of the disease, preventing early diagnosis of AHS. We describe a new case of AHS in a 6-year old-girl that evolved from a rapid onset myoclonic status into epilepsia partialis continua, with continuous multifocal asynchronous myoclonus and carrier of a de novo heterozygous mutation in POLG1 gene. EEG, MRI, and polygraphic changes that occurred during the first 3 months of the disease, and the clinical evolution during a 3-year follow-up period are described. EEG 1 month after onset documented rhythmic high-amplitude delta with superimposed polyspikes followed by progressive flattening of background activity. Brain MRI initially mimicked an immune-mediated encephalitis; within 3 months after onset, multifocal cortical signal abnormalities, diffuse cortical atrophy, and marked lactate peak suggested AHS syndrome. Epilepsy, which was initially drug-resistant, ceased 11 months later. After 3 years of follow-up, she still needs close medical support.

Conclusion Our case provides new mutation in POLG1 gene not described previously. We suggest detailed information in a case of AHS on temporal evolution of MRI and EEG patterns that may represent different stages of the disease course. Early identification of these patterns and their clinical correlates may provide insight into the pathogenetic mechanisms of the disease progression and help define diagnostic and therapeutic approaches.

Keywords

Alpers–Huttenlocher syndrome - epilepsia partialis continua - rhythmic high-amplitude delta activity with superimposed polyspikes - neuroimaging - POLG1 gene - drug-resistant - erratic myoclonus

• References

• 1 Naviaux RK, Nguyen KV. POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion. Ann Neurol 2004; 55 (5) 706-712
• 2 Ferrari G, Lamantea E, Donati A , et al. Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-gamma A. Brain 2005; 128 (Pt 4): 723-731
• 3 Boyd SG, Harden A, Egger J, Pampiglione G. Progressive neuronal degeneration of childhood with liver disease (“Alpers' disease”): characteristic neurophysiological features. Neuropediatrics 1986; 17 (2) 75-80
• 4 Engelsen BA, Tzoulis C, Karlsen B , et al. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain 2008; 131 (Pt 3): 818-828
• 5 Wolf NI, Rahman S, Schmitt B , et al. Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features. Epilepsia 2009; 50 (6) 1596-1607
• 6 Lee HF, Chi CS, Tsai CR, Chen CH. Epileptic seizures in infants and children with mitochondrial diseases. Pediatr Neurol 2011; 45 (3) 169-174
• 7 Hunter MF, Peters H, Salemi R, Thorburn D, Mackay MT. Alpers syndrome with mutations in POLG: clinical and investigative features. Pediatr Neurol 2011; 45 (5) 311-318
• 8 Khan A, Trevenen C, Wei XC, Sarnat HB, Payne E, Kirton A. Alpers syndrome: the natural history of a case highlighting neuroimaging, neuropathology, and fat metabolism. J Child Neurol 2012; 27 (5) 636-640
• 9 Obeso JA, Rothwell JC, Marsden CD. The spectrum of cortical myoclonus. From focal reflex jerks to spontaneous motor epilepsy. Brain 1985; 108 (Pt 1): 193-24
• 10 El-Hattab AW, Scaglia F. Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options. Neurotherapeutics 2013; 10 (2) 186-198
• 11 Cohen BH, Naviaux RK. The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders. Methods 2010; 51 (4) 364-373
• 12 National Institute of Environmental Health Sciences. Polymerase Gamma Gene Mutation Database. Available at http://tools.niehs.nih.gov/polg
• 13 Cohen BH, Chinnery PF, Copeland WC. POLG-related disorders. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, ed. GeneReviews [Internet]. Seattle, WA: 2010. [updated December 18, 2014]
• 14 Agostino A, Valletta L, Chinnery PF , et al. Mutations of ANT1, Twinkle, and POLG1 in sporadic progressive external ophthalmoplegia (PEO). Neurology 2003; 60 (8) 1354-1356
• 15 Harding BN. Progressive neuronal degeneration of childhood with liver disease (Alpers-Huttenlocher syndrome): a personal review. J Child Neurol 1990; 5 (4) 273-287
• 16 Saneto RP, Cohen BH, Copeland WC, Naviaux RK. Alpers-Huttenlocher syndrome. Pediatr Neurol 2013; 48 (3) 167-178